Tearsheet

Belite Bio (BLTE)

Market Price (9/4/2025): $65.39 | Market Cap: $2.1 Bil
Sector: Health Care | Industry: Biotechnology

Belite Bio (BLTE)

Market Price (9/4/2025): $65.39
Market Cap: $2.1 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0			Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1			Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -54 Mil
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.6%

0	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -54 Mil
2	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.6%

Market Valuation

	9/4/25	2024	2023	2022	2021
Share Price CYE	$65.39	$63.10	$45.75	$30.14
Market Cap CYE ($ Bil)	2.1	2.0	1.3	0.8	-
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	0.1	0.1	0.0	0.0
Enterprise Value ($ Bil)	0.0	2.0	1.3	0.8
Valuation Ratios
P/S TTM	0.0	0.0	0.0	0.0	0.0
P/EBIT TTM	-42.2	-53.4	-38.5	-47.7	0.0
P/E TTM	-43.1	-53.3	-38.5	-47.6	0.0
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5	4.5	6.7
P/EBIT TTM (Sector)	4.3	0.4	-1.9	-1.2	-0.4
P/E TTM (Sector)	-1.8	-2.2	-3.4	-2.2	-2.3

	9/4/25	2024	2023
Share Price CYE	$65.39	$63.10	$45.75
Market Cap CYE ($ Bil)	2.1	2.0	1.3
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	0.1	0.1
Enterprise Value ($ Bil)	0.0	2.0	1.3
Valuation Ratios
P/S TTM	0.0	0.0	0.0
P/EBIT TTM	-42.2	-53.4	-38.5
P/E TTM	-43.1	-53.3	-38.5
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5
P/EBIT TTM (Sector)	4.3	0.4	-1.9
P/E TTM (Sector)	-1.8	-2.2	-3.4

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BLTE Return	-	-	-	52%	38%	1%	109%
Peers Return	11%	18%	23%	15%	2%	8%	103%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ABBV, AMGN, GILD, REGN.
[3] 2025 data is for the year up to 9/3/2025 (YTD)

Better Bets than Belite Bio (BLTE)

	BLTE	Better Performance than BLTE
Metric	Value	Industry (Biotechnology)
Total Yield	-2.3%	ABBV (4.0%), AMGN (7.5%), GILD (7.3%), VRTX (3.5%), REGN (7.6%)

	BLTE	Better Performance than BLTE
Metric	Value	Sector (Health Care)
Total Yield	-2.3%	LLY (2.9%), JNJ (8.1%), ABBV (4.0%), UNH (10.4%), ABT (7.8%)

	BLTE	Better Performance than BLTE
Metric	Value	All Other Sectors
Total Yield	-2.3%	NVDA (2.1%), MSFT (3.4%), AAPL (3.3%), GOOGL (4.9%), AMZN (2.9%)

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Why Belite Bio Stock Moved: BLTE Stock Has Gained 117% Since 2022 Fiscal End, Primarily Due To Favorable Change In Revenues
2	BLTE Dip Buy Analysis
3	Belite Bio (BLTE) Valuation Ratios Comparison	Financials
4	Belite Bio (BLTE) Operating Cash Flow Comparison	Financials
5	Belite Bio (BLTE) Net Income Comparison	Financials
6	Belite Bio (BLTE) Operating Income Comparison	Financials
7	Belite Bio (BLTE) Revenue Comparison	Financials

	Title
0	ARTICLES
1	Why Belite Bio Stock Moved: BLTE Stock Has Gained 117% Since 2022 Fiscal End, Primarily Due To Favorable Change In Revenues
2	BLTE Dip Buy Analysis
3	Belite Bio (BLTE) Valuation Ratios Comparison
4	Belite Bio (BLTE) Operating Cash Flow Comparison
5	Belite Bio (BLTE) Net Income Comparison
6	Belite Bio (BLTE) Operating Income Comparison
7	Belite Bio (BLTE) Revenue Comparison

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	MMEX	MMEX Resources	∞%	-50.0%
2	TAWNF	Thai Airways International	3674.5%	3400.0%
3	NOKPF	Nok Airlines	2400.0%	81.8%
4	AYRWF	Ayr Wellness	509.5%	-94.6%
5	XELA	Exela Technologies	379.0%	-95.5%
6	SRNE	Sorrento Therapeutics	233.3%	900.0%
7	PGEN	Precigen	169.9%	324.1%
8	TLS	Telos	154.7%	89.2%
9	SATS	EchoStar	142.7%	179.1%
10	RLMD	Relmada Therapeutics	139.0%	182.7%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	TTOO	T2 Biosystems	-94.8%	-99.0%
4	NXTT	Next Technology	-86.5%	-89.4%
5	OTRK	Ontrak	-78.2%	-96.6%
6	SCGY	Scientific Energy	-72.7%	-26.9%
7	PPCB	Propanc Biopharma	-72.1%	-79.1%
8	MGAWF	Megaworld	-71.0%	-71.0%
9	PTTMF	PT Timah	-62.8%	-83.1%
10	PIGEF	Pigeon	-62.4%	-62.4%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

Peer Comparisons for Belite Bio

Financials

	BLTE	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Belite B.	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Mkt Price	65.36	401.00	211.92	286.92	112.71	577.90	249.42
Mkt Cap	2.1	102.9	374.7	154.4	140.3	60.7	121.6
Rev LTM	0	11,419	58,328	34,917	28,862	14,214	21,538
Op Inc LTM	-54	-199	13,695	8,192	10,797	3,841	6,016
FCF LTM	-	3,500	18,239	10,605	9,369	3,556	9,369
FCF 3Y Avg	-	1,984	20,273	8,590	8,397	3,248	8,397
CFO LTM	-	3,846	19,283	12,013	9,868	4,744	9,868
CFO 3Y Avg	-	2,324	21,154	9,753	8,949	4,518	8,949

Growth & Margins

	BLTE	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Belite B.	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Rev Chg LTM	-	10.5%	6.1%	12.9%	3.8%	5.4%	6.1%
Rev Chg 3Y Avg	-	11.0%	0.6%	10.0%	1.6%	0.3%	1.6%
Rev Chg Q	-	12.1%	6.6%	9.4%	1.8%	3.6%	6.6%
QoQ Delta Rev Chg LTM	-	2.9%	1.7%	2.3%	0.4%	0.9%	1.7%
Op Mgn LTM	-	-1.7%	23.5%	23.5%	37.4%	27.0%	23.5%
Op Mgn 3Y Avg	-	26.5%	27.2%	26.4%	39.2%	30.1%	27.2%
QoQ Delta Op Mgn LTM	-	2.0%	1.0%	1.6%	-0.0%	-0.2%	1.0%
CFO/Rev LTM	-	33.7%	33.1%	34.4%	34.2%	33.4%	33.7%
CFO/Rev 3Y Avg	-	22.5%	37.5%	32.0%	31.9%	33.6%	32.0%
FCF/Rev LTM	-	30.6%	31.3%	30.4%	32.5%	25.0%	30.6%
FCF/Rev 3Y Avg	-	19.2%	36.0%	28.2%	30.0%	24.1%	28.2%

Valuation

	BLTE	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Belite B.	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Mkt Cap	2.1	102.9	374.7	154.4	140.3	60.7	121.6
P/S	-	9.0	6.4	4.4	4.9	4.3	4.9
P/EBIT	-42.2	23.4	63.6	14.9	17.1	12.4	16.0
P/E	-43.1	28.3	99.6	23.3	22.2	13.6	22.8
P/CFO	-	26.8	19.4	12.8	14.2	12.8	14.2
Total Yield	-2.3%	3.5%	4.0%	7.5%	7.3%	7.6%	5.7%
Dividend Yield	0.0%	0.0%	3.0%	3.2%	2.8%	0.3%	1.6%
FCF Yield 3Y Avg	-	2.1%	7.3%	6.2%	8.0%	4.4%	6.2%
D/E	0.0	0.0	0.2	0.4	0.2	0.0	0.1
Net D/E	0.0	-0.0	0.2	0.3	0.1	-0.1	0.1

Returns

	BLTE	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Belite B.	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
1M Rtn	-0.5%	-13.2%	8.6%	-2.6%	-0.4%	3.6%	-0.5%
3M Rtn	0.8%	-10.2%	14.2%	-0.1%	3.8%	18.6%	2.3%
6M Rtn	9.3%	-17.5%	3.8%	-6.5%	-0.4%	-14.2%	-3.5%
12M Rtn	34.3%	-19.1%	11.8%	-11.2%	47.3%	-51.0%	0.3%
3Y Rtn	90.1%	42.7%	74.1%	30.3%	97.4%	-0.0%	58.4%
1M Excs Rtn	-3.4%	-16.1%	5.7%	-5.4%	-3.3%	0.7%	-3.3%
3M Excs Rtn	-7.6%	-18.1%	6.2%	-7.8%	-3.9%	9.8%	-5.7%
6M Excs Rtn	4.7%	-26.7%	-7.7%	-15.8%	-11.1%	-25.0%	-13.5%
12M Excs Rtn	19.0%	-32.8%	-2.4%	-24.7%	33.4%	-66.3%	-13.6%
3Y Excs Rtn	104.3%	-15.1%	17.5%	-24.3%	45.4%	-56.7%	1.2%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date		3/17/2025	3/12/2024	3/31/2023	4/29/2022	3/31/2023
Key Financials
Total Revenue	0	0	0	0	0	0
Ebitda	-50	-36	-31	-12	-10	-6
Operating Income	-54	-40	-32	-13	-10	-6
Net Income	-49	-36	-32	-13	-10	-6
EPS	-1.55	-1.18	-1.19	-0.63	-0.40	-0.24
Growth Rates
Total Revenue Growth	-	-	-	-	-	-
EBITDA Growth	-37.6%	-14.3%	-150.9%	-29.0%	-68.6%	-
Operating Income Growth	-47.9%	-26.3%	-147.0%	-30.9%	-70.6%	-
Net Income Growth	-39.9%	-14.3%	-150.1%	-30.9%	-68.0%	-
Margins
EBITDA Margin	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-
Cash & Debt
Total Cash	�	145	88	42	17	26
Total Debt	0	1	1	1	0	0
Net Debt / (Cash)	�	-145	-87	-41	-17	-26
Cash Flows
Net Cash from Operations	-	-29	-30	-11	-7	-4
Free Cash from Operations	-	-29	-30	-12	-8	-4
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/11/2025	5/14/2025	3/17/2025	11/12/2024	8/9/2024	5/14/2024	3/12/2024	11/14/2023	8/9/2023	5/11/2023	3/31/2023	11/14/2023
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda	-18	-16	-8	-10	-10	-8	-7	-11	-7	-7	-7	-3
Operating Income	-18	-16	-11	-10	-10	-8	-7	-11	-7	-7	-7	-3
Net Income	-16	-14	-10	-9	-9	-8	-7	-11	-7	-7	-7	-2
EPS	-0.50	-0.45	-0.32	-0.28	-0.31	-0.27	-0.24	-0.40	-0.26	-0.33	-0.31	-0.10
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	0	0	0	0	0	-
Ebitda TTM	-50	-43	-36	-35	-37	-33	-32	-31	-23	-18	-13	-
Operating Income TTM	-54	-47	-40	-35	-37	-33	-32	-31	-23	-19	-13	-
Net Income TTM	-49	-43	-36	-33	-35	-33	-32	-31	-23	-18	-13	-
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Growth	-68.0%	-86.3%	-10.1%	11.1%	-52.4%	-21.0%	-5.4%	-331.5%	-174.2%	-553.5%	-	-
Operating Income Growth	-68.0%	-86.3%	-64.7%	11.1%	-52.4%	-21.0%	-3.5%	-331.5%	-174.2%	-553.5%	-	-
Net Income Growth	-71.9%	-81.4%	-44.5%	20.6%	-39.4%	-14.2%	-3.0%	-355.1%	-184.9%	-544.4%	-	-
Margins Quarterly
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-	-	-	-	-	-
Cash & Debt
Total Cash	-	-	145	-	-	-	88	-	-	-	42	-
Total Debt	0	0	1	0	0	0	1	0	0	0	1	0
Net Debt / (Cash)	-	-	-145	-	-	-	-87	-	-	-	-41	-
Cash Flows Quarterly
FCF from Operations	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows TTM
FCF from Operations TTM	-	-	-	-	-	-	-	-	-	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-47.0%	-39.3%	-42.1%	-34.7%	-36.6%	-34.5%	-37.3%	-83.0%	-49.3%	-78.3%	-67.0%	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-36.2%	-29.9%	-36.7%	-31.6%	-32.0%	-34.3%	-42.4%	-59.5%	-41.3%	-53.0%	-31.9%	-

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$63.51
Market Cap ($ Bil)	2.1
First Trading Date	04/29/2022
Distance from 52W High	-24.1%
	50 Days	200 Days
DMA Price	$63.66	$62.89
DMA Trend	indeterminate	up
Distance from DMA	-0.2%	1.0%
	3M	1YR
Volatility	44.0%	54.6%
Downside Capture	46.73	27.95
Upside Capture	12.21	50.22
Correlation (SPY)	16.0%	12.9%
	5D	10D
Expected Return	4.9%	12.8%
Expected Excess Return	0.1%	-10.3%
Chance of Rise	60.0%	83.3%
Std Dev of Returns	3.2%	4.1%

BLTE Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.65	1.54	0.88	0.33	0.36	0.30
Up Beta	3.46	3.28	1.02	0.26	0.40	0.01
Down Beta	-0.22	0.79	2.04	0.47	0.21	0.43
Up Capture	109%	112%	25%	32%	41%	19%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	9	20	29	63	128	384
Down Capture	210%	38%	80%	32%	42%	67%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	12	21	33	62	120	361

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8152025
Short Interest: Shares Quantity	189,112
Short Interest: % Change Since 7312025	11.6%
Average Daily Volume	59,642
Days-to-Cover Short Interest	3.17
Basic Shares Quantity	32,585,043
Short % of Basic Shares	0.6%

SEC Filings

Expand for More

Report Date	Filing
6302025	6-K 6/30/2025
3312025	6-K 3/31/2025
12312024	20-F 12/31/2024
9302024	6-K 9/30/2024
6302024	6-K 6/30/2024
3312024	6-K 3/31/2024
12312023	20-F 12/31/2023
9302023	6-K 9/30/2023
6302023	6-K 6/30/2023
3312023	6-K 3/31/2023
12312022	20-F 12/31/2022
6302022	6-K 6/30/2022
12312021	424B4 12/31/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BLTE Return	-	-	-	52%	38%	1%	109%
Peers Return	11%	18%	23%	15%	2%	8%	103%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%
Monthly Win Rates [3]
BLTE Win Rate	-	-	62%	50%	42%	43%
Peers Win Rate	55%	55%	55%	53%	57%	63%
S&P 500 Win Rate	58%	75%	42%	67%	75%	57%
Max Drawdowns [4]
BLTE Max Drawdown	-	-	-	-63%	-29%	-16%
Peers Max Drawdown	-16%	-9%	-7%	-11%	-11%	-10%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

Belite Bio (BLTE)

Market Price (9/4/2025): $65.39 | Market Cap: $2.1 BilSector: Health Care | Industry: Biotechnology

Belite Bio (BLTE)

Market Price (9/4/2025): $65.39Market Cap: $2.1 BilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Belite Bio (BLTE)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Belite Bio

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/4/2025): $65.39 | Market Cap: $2.1 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (9/4/2025): $65.39
Market Cap: $2.1 Bil
Sector: Health Care
Industry: Biotechnology